Mallax Pharmaceuticals

Mallax Pharmaceuticals was established in Q4 2020 by Impilo together with Anders Larnholt, an experienced pharma executive, as a pharma company ‘ready-to-use’ with required pharmaceutical processes and licenses

Impilo’s ambition is to invest significant capital and resources in building a platform of established pharmaceuticals and OTC products for customers and patients across Europe – with a wide size range for any individual deal between EUR 10m and EUR 300m.

Responsible Partner:

Magnus Edlund

Impilo Board Members:

Magnus Edlund

Victor Steien


Pharmaceuticals / OTC


Anders Larnholt

Acquisition date:

December 2020